7-hydroxystaurosporine has been researched along with Disease Exacerbation in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agarwala, SS; Christensen, SD; Frankel, PH; Gandara, DR; Lara, PN; Li, T; Luu, T; Mack, PC; Margolin, KA | 1 |
| Amornphimoltham, P; Benavides, F; Conti, CJ; Gutkind, JS; Molinolo, AA; Patel, V; Sauk, J; Sausville, EA; Sriuranpong, V | 1 |
| Bok, R; Park, JW; Rini, BI; Scott, J; Shaw, V; Small, EJ; Weinberg, V | 1 |
| Beaulieu, B; Beelen, AP; Eastman, A; Ernstoff, MS; Johnston, N; Lewis, LD; Olszanski, AJ; Perez, RP; Rhodes, CH | 1 |
3 trial(s) available for 7-hydroxystaurosporine and Disease Exacerbation
| Article | Year |
|---|---|
A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; California; Cell Cycle; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Protein Kinase C; Protein Kinase Inhibitors; Skin Neoplasms; Staurosporine; Time Factors; Treatment Outcome | 2012 |
Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Adhesion Molecules; Disease Progression; Epithelial Cell Adhesion Molecule; Female; Flow Cytometry; Humans; Immunohistochemistry; Kidney Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Staurosporine; Time Factors; Treatment Outcome | 2004 |
Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Cell Cycle; Cisplatin; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Injections, Intravenous; Maximum Tolerated Dose; Neoplasms; Predictive Value of Tests; Staurosporine; Tissue Distribution; Treatment Outcome | 2006 |
1 other study(ies) available for 7-hydroxystaurosporine and Disease Exacerbation
| Article | Year |
|---|---|
Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Disease Progression; Enzyme Activation; Head and Neck Neoplasms; Humans; Immunohistochemistry; Mice; Mouth Mucosa; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Signal Transduction; Skin; Staurosporine; Time Factors | 2004 |